- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
CD276 Rabbit Polyclonal Antibody / B7-H3 Immunoregulatory Protein Antibody recognizes CD276, also known as B7-H3, a type I transmembrane glycoprotein belonging to the B7 family of immune regulatory proteins. CD276 contains extracellular immunoglobulin-like domains, a transmembrane segment, and a short intracellular tail. Two-domain and four-domain forms have been described, with the four-domain form predominating in humans. Extensive glycosylation influences the protein's apparent molecular weight and may contribute to its stability and molecular interactions at the cell surface.
B7-H3 participates in complex interactions involving immune cells and their surrounding tissue environment. Early investigations suggested that CD276 could enhance T-cell proliferation and interferon-gamma production, whereas subsequent studies reported inhibitory effects on T-cell activation and cytokine secretion. These contrasting observations indicate that its immunoregulatory activity depends on cellular context and experimental conditions. Although several potential binding partners have been proposed, the principal physiological receptor responsible for B7-H3 signaling remains incompletely established.
CD276 expression has been documented in numerous malignancies, including prostate, breast, ovarian, lung, and colorectal cancers. The protein may be expressed by malignant cells as well as tumor-associated stromal and vascular compartments. In several cancer types, increased B7-H3 expression has been associated with aggressive pathological characteristics, metastatic potential, and unfavorable clinical outcomes. However, these associations vary among tumor types and do not necessarily establish a direct causal relationship between CD276 abundance and disease progression.
Beyond its potential effects on immune surveillance, B7-H3 has been implicated in cellular migration, invasion, metabolic adaptation, and resistance to stress. Experimental studies suggest that CD276 may influence signaling pathways associated with tumor growth and interactions within the tumor microenvironment. The molecular mechanisms underlying these activities remain subjects of ongoing investigation, particularly because the protein's intracellular region lacks well-characterized signaling motifs.
The distribution of B7-H3 in malignant tissues has generated considerable interest in its potential as a therapeutic target. Investigational approaches include monoclonal antibodies, antibody-drug conjugates, and engineered cellular therapies directed against CD276-expressing cells. CD276 Rabbit Polyclonal Antibody provides a means of examining this immunoregulatory glycoprotein and investigating its relationship to tumor biology, immune interactions, and the molecular characteristics of malignant tissues.
For additional characterization of this tumor-associated immunoregulatory protein, see our CD276 Antibody B7H3/4345, a mouse monoclonal antibody supported by immunohistochemistry, western blot, and human protein microarray specificity data.
The stated application concentrations are suggested starting points. Titration of the CD276 Rabbit Polyclonal Antibody / B7-H3 Immunoregulatory Protein Antibody may be required due to differences in protocols and secondary/substrate sensitivity.
A portion of amino acids 493-522 from the human protein was used as the immunogen for the CD276 antibody.
Aliquot the CD276 antibody and store frozen at -20oC or colder. Avoid repeated freeze-thaw cycles.
B7-H3 antibody, B7 homolog 3 antibody, B7 homologue 3 antibody, B7RP-2 antibody, B7H3 antibody, CD276 protein antibody, B7-H3 glycoprotein antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.